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Novelty and Impact (Words=70) 1 
Pancreatic cancer (PC) has been inconsistently associated with alcohol consumption owing to 2 
the challenge of investigating a rare disease in prospective studies, providing a limited 3 
number of incident events.  Through a comprehensive evaluation that included 1,283 incident 4 
cases, our study indicated that baseline and lifetime alcohol intakes were positively related to 5 
PC, with stronger risks estimated for beer and spirits/liquors than wine intake. Associations 6 
were not modulated by smoking habits. 7 
 8 
Abstract (Words=243) 9 
Recent evidence suggested a weak relationship between alcohol consumption and pancreatic 10 
cancer (PC) risk. In this study, the association between lifetime and baseline alcohol intakes 11 
and the risk of PC was evaluated, including the type of alcoholic beverages and potential 12 
interaction with smoking. Within the European Prospective Investigation into Cancer and 13 
Nutrition (EPIC) study, 1,283 incident PC (57% women) were diagnosed from 476,106 14 
cancer-free participants, followed up for 14 years. Amounts of lifetime and baseline alcohol 15 
were estimated through lifestyle and dietary questionnaires, respectively. Cox proportional 16 
hazard models with age as primary time variable were used to estimate PC hazard ratios (HR) 17 
and their 95% confidence interval (CI). Alcohol intake was positively associated with PC risk 18 
in men. Associations were mainly driven by extreme alcohol levels, with HRs comparing 19 
heavy drinkers (>60 g/day) to the reference category (0.1-4.9 g/day) equal to 1.77 (95% CI: 20 
1.06, 2.95) and 1.63 (95% CI: 1.16, 2.29) for lifetime and baseline alcohol, respectively. 21 
Baseline alcohol intakes from beer (>40 g/day) and spirits/liquors (>10 g/day) showed HRs 22 
equal to 1.58 (95% CI: 1.07, 2.34) and 1.41 (95% CI: 1.03, 1.94), respectively, compared to 23 
the reference category (0.1-2.9 g/day). In women, HR estimates did not reach statistically 24 
significance. The alcohol and PC risk association was not modified by smoking status. 25 
Findings from a large prospective study suggest that baseline and lifetime alcohol intakes 26 
were positively associated with PC risk, with more apparent risk estimates for beer and 27 
spirits/liquors than wine intake. 28 
29 
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Introduction 1 
Pancreatic cancer (PC) is a major public health concern. It is one of the most fatal cancers 2 
worldwide, accounting for a mortality-incidence ratio close to 1, and a 7% survival beyond 3 
five years after diagnosis.1,2 The total number of deaths due to PC is expected to rise in the 4 
coming years among the American and European populations and is set to surpass breast, 5 
prostate, and colorectal cancers to become the second leading cause of cancer-related death 6 
after lung cancers.3,4 This evidence highlights the importance of understanding risk factors of 7 
PC to enhance its primary prevention. 8 
The majority of PC cases currently occurs in high-income countries, such as the United States 9 
and Western European countries, where incidence rates are nearly three times higher than in 10 
middle- and low-income countries.5 This incidence pattern suggests that PC occurrence is 11 
related to lifestyle factors specifically prevalent in the Western world. The etiology of PC has 12 
been extensively researched, leading to the identification of tobacco smoking, obesity, type-II 13 
diabetes mellitus and chronic pancreatitis as well as inherited genetic disorders as major risk 14 
factors.6–9  15 
In 2012, international expert panels reviewed the association between alcohol and cancer and 16 
considered the epidemiologic evidence for PC inconsistent, highlighting the possibility of 17 
residual confounding by smoking and the lack of knowledge on whether results differ by type 18 
of alcoholic beverages.6,10 The most recent prospective studies suggested that alcohol 19 
consumption may increase PC risk but with an excess risk limited to high levels of 20 
consumption.11–14 The majority of these investigations primarily focused on baseline alcohol 21 
intake, whereas two early analysis from the European Prospective Investigation on Cancer 22 
and Nutrition (EPIC) study indicated that neither baseline nor cumulative lifetime alcohol 23 
intake were related to PC risk.15,16 Recent meta-analyses have shown that alcohol intake 24 
increased the risk of PC by at least 15% in heavy drinkers consuming more than 25 g/day 25 
when compared to light drinkers.17,18 Although the association was also investigated among 26 
never smokers, as well as the interaction with tobacco smoking,11,12,14 it has been more often 27 
explored in case-control studies in comparison to prospective studies19 due to the small 28 
number of cases being both heavy drinker and never smoker.  29 
In the light of these findings, relationship between alcohol intake and PC risk was 30 
comprehensively examined in the EPIC study involving a larger number of incident PC cases 31 
than earlier evaluations,15,16 and presenting risk estimates according to lifetime and baseline 32 
intakes, as well as according to the type of alcoholic beverages and smoking habits. 33 
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Material and Methods 1 
EPIC is an ongoing multicenter prospective study aiming to investigate prospectively the 2 
etiology of cancer in relation to diet, lifestyle and environmental factors, and for which the 3 
study design has been previously describe in detail.20 From 1992 to 2000, a total of 521,324 4 
participants were recruited across 10 European countries, mostly from the general population, 5 
of which 70% are women, aged from 35 to 70 years. Exceptions were the French cohort 6 
(members of a health insurance for school and university employees), some of the Spanish 7 
and Italian centers (blood donors), Utrecht and Florence sub-cohorts (only breast cancer 8 
screening participants), and Oxford sub-cohort (vegetarians and ‘health conscious’ 9 
participants). The cohorts of France and Norway and the national sub-cohorts of Utrecht and 10 
Naples consist of women only. Approval for this study was obtained from the relevant ethical 11 
review boards of the participating institutions and study participants provided informed 12 
consent before they completed diet, lifestyle and medical questionnaires at baseline. 13 
Assessment of alcohol intake and covariates. Diet was assessed at recruitment by validated 14 
center-/country- specific dietary questionnaires20 designed to capture local-dietary habits with 15 
high compliance.21 Data on weight and height (self-reported in France, Norway and the UK 16 
Oxford center), occupational and physical activities, previous illness, smoking status and 17 
lifetime alcohol intake were collected through lifestyle questionnaires. 18 
Baseline alcohol intake was computed from the number of glasses of beer and/or cider, wine, 19 
sweet liquors and/or distilled spirits, and fortified wines drunk per day or week during the 12 20 
months preceding recruitment. For each country, an average daily alcohol intake expressed in 21 
grams per day was calculated based on the standard glass volume and ethanol content for each 22 
type of alcoholic beverage using information collected through 24-hour dietary recalls from a 23 
subgroup of the cohort.22–24 24 
Lifetime alcohol consumption was measured through the number of glasses from the different 25 
types of beverages consumed per week at 20, 30, 40, and 50 years of age, including the intake 26 
at recruitment. The average lifetime alcohol intake was calculated as a weighted average of 27 
intakes at different ages with weights equal to the time of exposure to alcohol at different 28 
ages. Information was available for 76.3% of the study participants, as data on lifetime 29 
alcohol exposure were not collected in Naples (Italy), Bilthoven (The Netherlands), Sweden, 30 
and Norway. 31 
Ascertainment of disease outcome and vital status. The identification of cancer cases during 32 
follow-up was based on population cancer registries in 7 of the participating countries 33 
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(Denmark, Italy, Netherlands, Norway, Spain, Sweden, and the United Kingdom), and on a 1 
combination of methods, including health insurance records, contacts with cancer and 2 
pathology registries, and active follow-up of EPIC participants and their next of kin (France, 3 
Germany, and Greece). Mortality data were collected from, either the cancer, or mortality 4 
registries at the regional or national level. Currently, the vital status is known for 98.4% of all 5 
EPIC participants, as well as the proportion of participants who had emigrated to another 6 
country, withdrew or had unknown vital status (1.6%).  7 
For the present study, we used information on the most recent vital status and cancer 8 
diagnosis update. The follow-up period ended as follows: December 2009 (Varese, Murcia), 9 
December 2010 (Florence, Ragusa, Turin, Asturias, Bilthoven, and Utrecht), December 2011 10 
(Granada, Navarra, San Sebastian, and Cambridge), December 2012 (Oxford, Umeå, 11 
Denmark, and Norway), and December 2013 (Malmö). For France, Germany, Greece and 12 
Naples, the end of follow-up was considered to be the last known contact with study 13 
participants: June 2008 for France, December 2009 for Heidelberg and Potsdam, December 14 
2010 for Naples and December 2012 for Greece. Cases of PC defined in this study were 15 
primary incident exocrine tumor of the pancreas. They were coded according to International 16 
Classification of Diseases-Oncology (3rd edition), including all invasive pancreatic cancers 17 
coded as C25 (C25.0–C25.3, C25.7–C25.9). As they represent around 95% of PC cases, this 18 
study focused only on exocrine PC, while endocrine tumors of the pancreas were not 19 
considered (C25.4). Microscopically confirmed PC represented 67% of the cases (n=854) 20 
based on histology, cytology or hematology reports. Other cases were obtained from clinical 21 
or surgical observations (n=344), medical imaging technics (n=57), death certificates (n=17) 22 
and laboratory techniques (n=11). 23 
Statistical analysis. EPIC participants without lifestyle or dietary information (n= 6,902), 24 
participants with ratio of estimated energy intake over energy requirement in the top or 25 
bottom 1% (n=10,241),25 prevalent cancer cases (n=21,401), PC cases with missing date of 26 
diagnosis (n=18), participants with missing follow-up information (n=18) and PC cases 27 
having a neuroendocrine or endocrine tumor (n=54) were excluded. For lifetime alcohol 28 
analysis, participants without information on past alcohol use were excluded (n=112,841). 29 
The association between alcohol intake and PC incidence was evaluated using multivariable 30 
Cox proportional hazard models. Age was the primary time variable, and Breslow’s method 31 
was adopted for handling ties.26 The time at entry was the age at recruitment, whereas the exit 32 
time was the age at cancer diagnosis, death, loss, or end of follow-up, whichever came first. 33 
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All models were stratified by study center to control for different effects in questionnaires, 1 
follow-up procedures and other center-specific features.25 To further control for the effect of 2 
age as possible confounding, models were also stratified by age at recruitment in 1-year 3 
categories. Separate models were run by gender to account for the behavioral differences of 4 
alcohol uses between men and women. Baseline and lifetime alcohol intake were first 5 
modeled by categories, as non-consumers, 0.1-4.9 g/day (reference category), 5-14.9 g/day, 6 
15-29.9 g/day, 30-59.9 g/day and >60 g/day. In women, the last two categories were collapsed 7 
into a ≥ 30 g/day group. In analyses on lifetime alcohol intake, former drinkers at baseline 8 
were separated out from never consumers. Overall tests for significance of HRs related to 9 
alcohol in categories were determined by p-values comparing Wald test statistics to a χ² 10 
distribution with degree of freedom equal to the number of alcohol categories minus one. 11 
Analyses were also carried out in continuous, expressing HRs per 12 g/day increase of alcohol 12 
intake as 12 grams of alcohol corresponds to about one standard glass of either wine, beer or 13 
spirits/liquors. Tests for trend were computed accordingly.  14 
The following confounding variables were consistently included in all analyses: smoking 15 
intensity (never; current, 1-15 cig/day; current, 16-25 cig/day; current +26 cig/day; former, 16 
quit<10 years; former, quit 11-20 years; former, quit +20 years, current, pipe/cigar 17 
occasionally, unknown (n=7,921)), education level (no degree, primary school, secondary 18 
school, technical or professional school, university degree, unknown (n=10,706)), physical 19 
activity index (inactive, moderately inactive, moderately active, active, unknown 20 
(n=8,823))27, type 1 and type 2 diabetes mellitus status combined (no, yes, unknown 21 
(n=2,324)), body mass index (BMI) in kg.m-2 (continuous), height in cm (continuous). The 22 
inclusion of energy intake from non-alcohol sources to perform iso-caloric comparisons and 23 
partially control for errors in alcohol estimation did not alter the magnitude or risk estimates, 24 
and was not pursued. Models evaluating lifetime alcohol consumption were further adjusted 25 
on the duration of alcohol drinking (in years), time since quitting (in years), and an indicator 26 
variable for drinkers. Associations between alcohol subtypes, namely beer, wine and 27 
spirits/liquors and PC were assessed in adjusted models for energy intake from alcohol 28 
sources other than the one under evaluation using the following categories: never, 0.1–2.9 29 
g/day (reference), 3–9.9, 10–19.9, 20–39.9 and ≥ 40 g/day. For women, the two last 30 
categories were merged into a ≥ 20 g/day group. All models were compatible with the 31 
proportional hazards assumption, assessed through analyses of Schoenfeld residuals.28 32 
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Dose-response analyses were performed for baseline and lifetime alcohol intake in men. 1 
Potential departures from linearity in the association between alcohol intakes and PC were 2 
examined by fitting restricted cubic spline models29 with alcohol category-specific knots 3 
placed at 0.1, 5, 30, 60 and 100. Non-linearity was evaluated by comparing the difference in 4 
log-likelihood of models with linear term and fractional polynomials to a χ² distribution.  5 
Effect modification in the relationship between alcohol and PC risk by, in turn, smoking 6 
status (never, current smokers), sex and country was evaluated through comparisons of 7 
models with and without interaction terms. The differences in log-likelihood were compared 8 
to a χ² distribution, with degrees of freedom equal to the total number of interaction terms 9 
minus one. For analysis by smoking status, parameter estimates were not altered by the 10 
inclusion in the models of smoking duration and age at smoking initiation (data not shown). 11 
Sensitivity analyses were performed to assess the robustness of the findings. First, as reverse 12 
causation may bias the association between alcohol and PC, cases occurring during the first 2 13 
years of follow-up were further excluded. Second, models on baseline alcohol intake in 14 
women were further adjusted for baseline information for menopausal status, ever use of 15 
hormone therapy, and number of full-term pregnancies. Finally, in the absence of information 16 
on chronic pancreatitis in EPIC, a sensitivity analysis was carried out to account for the 17 
potential confounding role of chronic pancreatitis (Z) between baseline alcohol intake (X) and 18 
risk of pancreatic cancer (D) using external information.30 A PC HR for baseline heavy 19 
drinkers (>60g/day) vs. moderate drinkers (0.1-4.9g/day) not adjusted for chronic pancreatitis 20 
in EPIC was estimated as large as 1.64 (95% CI: 1.22, 2.21), for men and women combined. 21 
Assuming values from the literature for relative risk estimates of chronic pancreatitis 22 
associated with alcohol intake greater than 25 g/day compared to the never drinkers ranging 23 
from 2 to 6,31,32 pancreatitis prevalence among moderate drinkers ranging from 0.005 to 24 
0.0232 and relative risk estimates of PC associated with chronic pancreatitis ranging from 1.5 25 
to 15,33–35 PC HR for heavy drinkers vs. moderate drinkers adjusted for chronic pancreatitis 26 
were estimated. 27 
Two-sided p-values were provided with nominal level of statistical significance set to 5%. 28 
Analyses were performed using Stata.36 29 
 30 
Results 31 
EPIC population characteristics. This study was based on a population of 476,106 32 
participants, 70% women, with an overall median age at recruitment of 52 years. Within a 33 
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mean follow-up time of 14 years, and a total of 6,640,000 person-years, 1,283 incident 1 
pancreatic cancers were diagnosed (727 women) as reported in Table 1, with a median age at 2 
diagnosis of 67 years and age standardized incidence rate equal to 5.4 per 100,000 person-3 
years. 4 
Lifetime and baseline alcohol consumptions were 2- and 4-fold higher in men than in women, 5 
respectively. On average, beer and wine represented, respectively, 35% and 50% of total 6 
alcohol intake in men, and 12.5% and 63% in women. These patterns of consumption were 7 
consistent across countries in women, while consumptions were more heterogeneous in men. 8 
The proportion of non-drinkers was higher in women than in men. Men and women non-9 
drinkers (< 0.1 g/day) differed by their educational attainment, physical activity level and 10 
diabetes mellitus status when they were compared to alcohol consumers. Percentage of 11 
smokers at recruitment was higher among alcohol drinkers than among alcohol non-drinkers. 12 
Characteristics by categories of baseline alcohol intake are shown into the Table 2. 13 
Baseline alcohol intake. In men, baseline alcohol intake was statistically significantly 14 
associated with PC risk, with HR comparing alcohol intake greater than 60 g/day to the 15 
reference category (0.1-4.9g/day) equal to 1.63 (95%CI: 1.16, 2.29; pWald=0.03), as reported 16 
in Table 3. The association remained statistically significant when baseline alcohol intake was 17 
modelled as a continuous variable (HR for every increment of 12g/day: 1.05; 95% CI: 1.01, 18 
1.09; ptrend=0.02). For women, no statistically significant association between baseline alcohol 19 
intake and PC risk was observed, either as a categorical (pWald=0.68) or as a continuous (HR 20 
for every increment of 12g/day: 1.04; 95% CI: 0.97, 1.12; ptrend=0.28) exposure.   21 
Lifetime alcohol intake. Compared to the reference category, HR for men heavy drinkers (>60 22 
g/day) was 1.77 (95% CI: 1.06, 2.95) without overall statistical significance among categories 23 
(pWald=0.23), as reported in Table 3. Analyses in continuous showed HR for a 12 g/day 24 
increase equal to 1.06 (95% CI: 1.02, 1.10; ptrend<0.01). No statistically significant 25 
associations were observed in women. 26 
Type of alcoholic beverages. Mutually adjusted HR estimates for baseline alcoholic beverages 27 
are shown in Figure 1. Beer consumption was positively associated with PC risk with a 9% 28 
(95% CI: 1.02, 1.15; ptrend=0.01) and a 22% (95% CI: 1.03, 1.44; ptrend=0.02) risk increase for 29 
12 g/day in men and women, respectively. The highest levels of beer consumption (>40 g/day 30 
in men and >20 g/day in women) were statistically significantly associated with PC risk 31 
compared to the reference category (0.1-2.9 g/day) with HR equal to 1.58 (95% CI: 1.10, 32 
2.40) and 2.04 (95% CI: 1.13, 3.68) for men and women, respectively. Spirits/liquors in men 33 
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were associated with a 17% higher risk (95% CI: 1.04, 1.32; ptrend=0.01) for a 12 g/day 1 
increase, while no relationships were observed in women. Wine intake was not associated 2 
with PC risk, consistently in men and women. Similar results were observed for lifetime 3 
alcohol intake from the different beverages and PC risk (Supplementary Figure 1). 4 
Dose-response relationship. Figure 2 illustrates the dose-response relationship of the baseline 5 
and lifetime alcohol intake and PC risk in men, using restricted cubic splines. The trend for 6 
baseline and lifetime alcohol intake suggests a linear-shaped association, without evidence for 7 
departure from linearity either for baseline (pnon-linearity=0.83) or lifetime alcohol (pnon-8 
linearity=0.57). 9 
Evaluating heterogeneity. Heterogeneity tests by sex and country for baseline alcohol intake 10 
were not statistically significant, with p-values equal to 0.63 (data not shown) and 0.33 11 
(Supplementary Figure 2), respectively. Alcohol intake was not associated with PC risk 12 
among never smokers with HRs per 12g/day increase equal to 1.06 (95%CI: 0.98, 1.15; 13 
ptrend=0.13), unlike current smokers with HR equal to 1.05 (95%CI: 1.00, 1.11; ptrend=0.04). 14 
However, the overall interaction test for heterogeneity between alcohol and smoking status 15 
was not statistically significant (pheterog=0.84) (Table 4). Thus, the association between 16 
baseline alcohol and PC risk was not different across smoking status. 17 
Sensitivity analyses. After exclusion of the first two years of follow-up no substantial 18 
differences in results was observed in the association with baseline alcohol intake (data not 19 
shown). Among women, adjustment for menopausal status, ever use of hormone therapy, and 20 
number of full-term pregnancies in women did not alter estimates appreciably. The sensitivity 21 
analysis for external adjustment by history of chronic pancreatitis indicated that unadjusted 22 
HR estimate comparing baseline heavy drinkers (>60 g/day) vs. moderate drinkers (0.1-4.9 23 
g/day) was marginally attenuated for estimates of relative risk between alcohol and chronic 24 
pancreatitis as large as 4 and estimates of the PC relative risk associated with chronic 25 
pancreatitis not exceeding 5. Larger attenuations of HR estimates were observed for more 26 
extreme scenarios, as displayed in Supplementary Table 1. 27 
 28 
Discussion 29 
In this study, alcohol was positively associated with PC risk in men, the relation being 30 
particularly apparent among heavy drinkers compared to light drinkers, consistently for 31 
baseline and lifetime alcohol intakes, controlling for a comprehensive list of confounding 32 
factors. There was no statistically significant association between alcohol consumption and 33 
11 
 
PC in women. Analyses by alcoholic subtypes showed positive relationships for beer and 1 
spirits/liquors but not for wine. These results were virtually unaltered after sensitivity 2 
analyses. 3 
These findings support observations from other prospective studies.11,12,14,37,38 Our results 4 
showed that each 12 g/day of alcohol in men was linearly associated with a 5% increase in PC 5 
risk for baseline intakes, with a stronger association with the largest amounts of alcohol 6 
greater than 60 g/day, consistently with results from the most recent meta-analyses.13,17,18. 7 
While alcohol drinking has been related to PC risk in men, fewer studies found an association 8 
in women.14,37 Women drink generally less than men,39 as it was notably the case in the EPIC 9 
study, the chance to observe a significant association with PC risk is weaker in women, 10 
particularly if such association is apparent at high level of alcohol intake. However, no 11 
evidence for heterogeneity across genders between alcohol and PC risk emerged in our study 12 
(pheterog=0.63), suggesting that an association with PC risk in women would have been 13 
observed if they were showing exposure to alcohol as high as levels observed in men.  14 
Our study used information on lifetime alcohol intake, less often investigated in relation to PC 15 
risk. It revealed a statistically significant positive relationship with total lifetime alcohol 16 
consumption in men, whether it was modelled as continuous variable with a 6% increase risk 17 
for 12g/day or as categories, with men with the highest level of lifetime consumption 18 
(>60g/day) having a 77% higher risk when compared to the light drinkers category. Although, 19 
one case control study from California showed a more than three-fold significantly increased 20 
OR for those with a history of binge drinking,40 this association has not been shown in 21 
previous prospective analyses.15,16,40 22 
Specific analyses on alcohol subtypes in this study showed that PC risk was statistically 23 
significantly associated with spirits/liquors and beer in men, consistently using baseline and 24 
lifetime intake. In women, results were more heterogeneous, showing associations with beer 25 
intake at baseline, but not with lifetime intake. These findings are in line with previous studies 26 
showing spirits/liquors consumption frequently associated with PC risk.12,14,16,18,37,38 However, 27 
the association between beer consumption and PC risk was not reported in recent prospective 28 
studies, especially in women. Our results also showed no association with wine intakes, 29 
consistent observations with the other prospective studies.12,14,16,18,37 Moreover, country-30 
specific associations showed HR homogeneous estimates despite the variability of drinking 31 
patterns across EPIC countries. 32 
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The consumption of alcoholic beverages leads to the production of acetaldehyde, the most 1 
important metabolite derived from ethanol which increases the production of reactive oxygen 2 
species and DNA-adducts.41 Acetaldehyde was classified as carcinogenic in 2012 by the 3 
IARC Monograph program.10 Although oxidative stress produced by ethanol may induce 4 
damage in pancreatic tissues through lipid peroxidation,42,43 associations observed in this 5 
study varied depending on alcoholic subtypes. In vitro models investigating non-alcoholic 6 
compounds of alcoholic beverages have shown that beer, unlike pure ethanol or wine, may 7 
dose-dependently increase amylase secretion of rat’s acinar cells, and potentially disturb 8 
exocrine activity of the pancreas through alteration of cells’ functions.44 In parallel, the 9 
absence of association between wine and PC risk could be partially explained by the fact that 10 
wine contains molecules with anti-oxidative properties like polyphenols that may counteract 11 
ethanol.45 Resveratrol, a well-known polyphenolic compound of wine, has been reported to 12 
suppress cell transformation, to induce apoptosis through a p53-dependent pathway and to 13 
have chemo-preventive effects.46 More recently, in vitro and ex-vivo models have shown 14 
resveratrol suppressive action on pancreatic cells through inhibition of leukotriene A4 15 
hydrolase, an enzyme involved into pancreatic cancer cells growth.47  16 
It has been suggested that cigarette smoking in combination to ethanol may be associated with 17 
pancreatic stellate cells activation in cells culture, which are the cells responsible for pancreas 18 
fibrosis - a pre-cancerous lesion of PC.48 Despite some evidence for interaction between 19 
smoking and alcohol consumption on PC risk in case-control studies,19 this finding has not 20 
been replicated in prospective studies,11,12,14 possibly due to the lack of sufficient statistical 21 
power. In this study, no interaction between alcohol and smoking was observed, consistently 22 
with one large American prospective study.14 This evidence lends further support to the 23 
hypothesis that the relationship between alcohol and PC risk does not depend on smoking. 24 
Our study has several strengths and limitations. We took advantage of the large number of PC 25 
cases accrued in the EPIC study over a median of 14 years follow up, larger than previous 26 
evaluations within EPIC,15,16 where no association was observed between alcohol intake and 27 
PC. However, as EPIC participants are volunteers, they may be healthier and not 28 
representative of the general population. Thus, the variability of alcohol intake could be lower 29 
than in the general population. Moreover, self-reported assessments of alcohol intake are 30 
prone to measurement errors, and could have biased the estimates of the association between 31 
alcohol and PC risk. However, a previous calibration study in EPIC showed an absence of 32 
impact in the assessment of the diet/disease association.25  33 
13 
 
Study subjects with heavy alcohol consumption are susceptible to develop chronic 1 
pancreatitis,49 a known risk factor for PC.50 Accounting for chronic pancreatitis may provide 2 
useful information on the mechanism of the relationship between alcohol and PC risk. To 3 
address this, a sensitivity analysis was performed. For this analysis to be informative, a priori 4 
assumptions were set using evidence from the literature, i.e. the relative risk estimates of 5 
chronic pancreatitis associated with PC risk,35 the prevalence of chronic pancreatitis among 6 
moderate drinkers32 and the relative risk estimates of chronic pancreatitis comparing extreme 7 
to light alcohol drinkers.31 The sensitivity analysis suggests that PC HR estimate in relation to 8 
alcohol intake was not substantially altered when information on chronic pancreatitis was 9 
accounted for, thus suggesting that alcohol intake exerts its carcinogenic role only partially 10 
through chronic pancreatitis. 11 
 12 
Conclusion 13 
In summary, our study has shown a moderate but statistically significant increase in PC risk 14 
with high alcohol intake, either baseline or lifetime, and particularly with beer and 15 
spirits/liquors. These findings provide epidemiologic evidence for the role of alcohol 16 
consumption as a potential carcinogen of the pancreas. 17 
18 
14 
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Table 1. Country- and sex-specific frequencies of PC cases and other characteristics of the study population. 
 
Participants  PC cases Follow-up (years)1 PY
2
 
Age 
(years)3 
Baseline 
alcohol 
(g/day)4 
BNC2  
Baseline 
beer 
(g/day)4 
Baseline 
wine 
(g/day)4 
Baseline 
spirits/liquors 
(g/day)4 
Lifetime 
alcohol 
(g/day) 4  
% 
LNC2 
Men                                   
Italy 14,023 35 14 195,883 50 24 (1-54) 4 2 (0-3) 20 (0-47) 2 (0-5) 24 (2-49) 3 
Spain 15,138 55 16 239,109 50 28 (0-67) 15 3 (0-9) 22 (0-56) 3 (0-11) 43 (4-91) 4 
United Kingdoms 22,848 69 14 329,209 53 13 (0-34) 6 5 (0-22) 5 (0-12) 2 (0-3) 15 (1-34) 2 
The Netherlands 9,627 20 15 140,422 44 18 (0-44) 9 10 (0-29) 4 (0-10) 4 (0-11) -6 -6 
Greece 10,814 25 10 112,787 52 18 (0-44) 10 4 (0-9) 9 (0-26) 5 (0-15) 30 (0-74) 6 
Germany 21,177 72 10 219,536 53 24 (2-53) 4 15 (0-40) 8 (0-22) 2 (0-7) 27 (5-56) 1 
Sweden 22,304 93 16 358,863 51 9 (0-23) 10 4 (0-8) 2 (0-8) 2 (0-7) -6 -6 
Denmark 26,287 187 15 382,609 56 28 (4-62) 2 14 (1-36) 10 (0-30) 3 (0-8) 21 (5-41) 1 
All Men 142,218 556 14 1,978,417 53 20 (0-50) 7 7 (0-22) 10 (0-30) 3 (0-7) 26 (3-55) 2 
Women                                   
France 67,395 56 13 869,319 52 11 (0-29) 14 1 (0-2) 9 (0-24) 0 (0-1) 7 (0-17) 15 
Italy 30,511 69 14 434,978 51 9 (0-24) 23 1 (0-1) 7 (0-24) 0 (0-1) 6 (0-17) 15 
Spain 24,848 51 16 398,811 48 4 (0-14) 53 1 (0-2) 3 (0-12) 0 (0-0) 4 (0-14) 39 
United Kingdoms 52,56 119 15 793,462 48 7 (0-17) 6 1 (0-4) 5 (0-12) 1 (0-3) 9 (0-21) 4 
The Netherlands 26,906 73 14 384,205 53 8 (0-24) 18 1 (0-2) 4 (0-11) 1 (0-3) 7 (0-18) 7 
Greece 15,233 19 11 168,491 54 3 (0-9) 35 1 (0-1) 2 (0-6) 1 (0-2) 3 (0-10) 33 
Germany 27,379 44 10 284,937 48 9 (0-23) 5 2 (0-7) 6 (0-17) 1 (0-1) 7 (1-15) 2 
Sweden 26,368 111 17 442,242 51 5 (0-13) 18 1 (0-3) 2 (0-7) 0 (0-1) -6 -6 
Denmark 28,719 138 15 432,414 56 14 (1-34) 3 3 (0-7) 8 (0-30) 2 (0-5) 9 (1-19) 18 
Norway 33,969 47 13 452,121 48 3 (0-7) 21 1 (0-2) 2 (0-5) -5 -6 -6 
All women 333,888 727 14 4,660,980 51 8 (0-22) 17 1 (0-4) 5 (0-15) 1 (0-2) 7 (0-17) 11 
All participants 476,106 1283 14 6,639,397 52 12 (0-32) 14 3 (0-8) 7 (0-21) 1 (0-3) 13 (0-31) 8 
1 Means;  
2 PY: Person-years; BNC: Percentage of baseline non-consumers (<0.1 g/day); LNC: Percentage of lifetime never consumers (<0.1 g/day);   
3 Medians; 
4 Means (10th-90th percentiles);  
5 Information on alcohol coming from spirits/liquors not available in Norway; 
6 Information on lifetime alcohol not collected in Naples (Italy), Bilthoven (The Netherlands), Sweden, and Norway.  
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Table 2. Baseline characteristics of the EPIC participants by categories of baseline alcohol intake1. 
 
 
 Baseline alcohol intake categories (g/day) 
Men   Total < 0.1 0.1 - 4.9 5 - 14.9 15 - 29.9 30 - 59.9 > 60 
Number of participants (n) 142,219 9,709 30,494 37,890 29,450 25,272 9,404 
Number of PC cases - 556 40 95 134 120 104 63 
Person-Years - 1,978,418 131,552 433,917 534,503 405,407 347,434 125,605 
Age at recruitment (years) 52 ± 10 54  ± 11 51  ± 12 52  ± 11 52  ± 9 53  ± 9 53  ± 8 
Height (cm) 175 ± 7 172  ± 8 175  ± 7 175  ± 7 175  ± 7 175  ± 7 174  ± 7 
Weight (kg) 81 ± 12 80  ± 13 80  ± 12 81  ± 12 81  ± 11 82  ± 12 83  ± 13 
BMI (kg/m²) 27 ± 4 27  ± 4 26  ± 4 26  ± 4 26  ± 3 27  ± 4 27  ± 4 
Diabetes mellitus (%) 4 7 4 3 3 3 4 
Smokers at recruitment (%) 29 29 23 25 29 36 49 
Participants moderately active (%) 24 21 23 24 25 25 25 
Participants with at least a university degree (%) 27 15 23 29 31 29 22 
Energy from non-alcohol drinking (kcal/day) 2,268 ± 637 2,282  ± 686 2,222  ± 659 2,260  ± 626 2,297  ± 620 2,277  ± 620 2,318  ± 637 
Lifetime alcohol intakes (g/day) 26 ± 29 23  ± 47 10  ± 20 15  ± 15 24  ± 18 38  ± 23 65  ± 41 
Baseline alcohol intakes (g/day) 20 ± 23 0  ± 0 2  ± 1 9  ± 3 21  ± 4 42  ± 8 82  ± 25 
Women  Units  < 0.1 0.1 - 4.9 5 - 14.9 15 - 29.9 > 30   
Number of participants (n) 333,887 56,754 132,159 89,804 35,695 19,475 - 
Number of PC cases - 727 127 278 187 81 54 - 
Person-Years - 4,660,979 799,607 1,841,850 1,261,568 490,471 267,483 - 
Age at recruitment (years) 51 ± 10 52  ± 9 50  ± 10 51  ± 10 51  ± 9 52  ± 8 - 
Height (cm) 162 ± 7 160  ± 7 163  ± 7 163  ± 6 163  ± 6 163  ± 6 - 
Weight (kg) 66 ± 12 68  ± 13 66  ± 12 65  ± 11 64  ± 10 65  ± 11 - 
BMI (kg/m²) 25 ± 4 26  ± 5 25  ± 5 24  ± 4 24  ± 4 24  ± 4 - 
Diabetes melitus (%) 2 4 2 1 1 2 - 
Smokers at recruitment (%) 19 17 18 18 22 31 - 
Participants moderately active (%) 27 22 29 28 27 26 - 
Participants with at least a university degree (%) 23 13 20 28 30 32 - 
Energy from non-alcohol drinking (kcal/day) 1,877 ± 529 1,831  ± 534 1,845  ± 521 1,910  ± 520 1,963  ± 540 1,915  ± 558 - 
Lifetime alcohol intakes (g/day) 7 ± 9 1  ± 6 3  ± 5 8  ± 7 14  ± 9 23  ± 14 - 
Baseline alcohol intakes (g/day) 8 ± 12 0  ± 0 2  ± 1 9  ± 3 21  ± 4 43  ± 15 - 
1
 Means ± SD are presented for continuous variables, frequencies for categorical variables. 
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Table 3. Hazard Ratio (HR) estimates (95% CI) for baseline and lifetime alcohol intakes and PC. 
Men Baseline alcohol   Lifetime alcohol 
  cases PY HR1 95%CI cases PY HR2 95%CI 
Continuous (12 g/day)3                 
556   1,978,417  1.05 (1.01, 1.09) 429   1,460,432  1.06 (1.02, 1.10) 
ptrend 0.02 <0.01 
Categories (g/day)                 
Ex-consumers - - - - 24        61,485  1.78 (0.75, 4.22) 
Non consumers 40      131,552  1.23 (0.84, 1.79) 4        33,366  0.53 (0.16, 1.74) 
0.1 - 4.94 101      439,915  1.00 (Ref) 41      176,469  1.00 (Ref) 
5 - 14.9 132      532,427  0.99 (0.76, 1.29) 119      400,402  1.22 (0.82, 1.81) 
15 - 29.9 116      403,985  1.11 (0.83, 1.47) 116      389,206  1.26 (0.84, 1.90) 
30 - 59.9 104      345,443  1.10 (0.82, 1.47) 88      287,583  1.42 (0.93, 2.17) 
≥60 63      125,095  1.63 (1.16, 2.29) 37      111,921  1.77 (1.06, 2.95) 
pWald5       0.03       0.23 
Women Baseline alcohol Lifetime alcohol 
  cases PY HR1 95%CI cases PY HR2 95%CI 
Continuous (12 g/day)3                 
727   4,660,980  1.04 (0.97, 1.12) 537   3,486,009  1.01 (0.88, 1.14) 
ptrend 0.28 0.90 
Categories (g/day)                 
Ex-consumers - - - - 31      176,499  1.07 (0.54, 2.11) 
Non consumers 127      799,607  0.98 (0.78, 1.23) 63      495,243  0.72 (0.47, 1.10) 
0.1 - 4.94 280   1,852,494  1.00 (Ref) 210   1,296,401  1.00 (Ref) 
5 - 14.9 187   1,257,465  1.00 (0.82, 1.21) 165   1,052,229  1.06 (0.85, 1.34) 
15 - 29.9 80      487,565  1.11 (0.86, 1.44) 59      382,037  1.16 (0.85, 1.59) 
≥30 53      263,849  1.16 (0.85, 1.59) 9        83,601  0.93 (0.47, 1.85) 
pWald5       0.68       0.79 
1
 Models for baseline alcohol intake were stratified by center and age at recruitment. Systematic adjustment was undertaken for smoking intensity, physical activity 
level, educational attainment, diabetes status, BMI, height; 
2
 Models for lifetime alcohol intake were stratified by center and age at recruitment. Systematic adjustment was undertaken for smoking intensity, physical activity 
level, educational attainment, diabetes status, BMI, height, duration of alcohol drinking, time since quitting, and an indicator variable for drinkers; 
3
 12g of alcohol correspond to about one standard glass of either wine, beer or spirits;  
4
 The category 0.1 to 4.9 g/days was used as the reference category; 
5
 Wald test for overall significance, according to the χ2 distribution with degrees of freedom equal to the number of categories minus one. 
 Figure 1. Baseline intake of beer, wine and spirits/liquors (g/day) and Hazard Ratio (HR) of pancreatic cancer in men and women. 
 
 
1
 Models for baseline alcohol intake by subtypes were stratified by center and age at recruitment. Systematic adjustment was undertaken for smoking intensity, physical 
activity level, educational attainment, diabetes status, BMI, height, and baseline energy intake from other alcohol subtypes; 
2
 pWald for overall significance across categories were performed according to the χ2 distribution with degrees of freedom equal to the number of categories minus one. Trend 
tests were performed for continuous variable; 
3
 The category of light drinkers was used as the reference category (0.1-2.9 g/day for beer and wine, and 0.1-1.9 g/day for spirits/liquors); 
4
 12g of alcohol correspond to about one standard glass of either wine, beer or spirits/liquors. 
 
Table 4: Hazard Ratio1 (95% CI) for overall pancreatic cancer risk by categories of baseline alcohol use (g/day) and smoking status (never and 
current smokers at baseline). 
All participants Never smokers 
 
Current smokers   
 
Cases PY HR3 (95%CI)   Cases PY HR3 (95%CI) pheterogeneity4 
Continuous (12 g/day)2                     
 
494        3,286,210 1.06 (0.98, 1.15)   422     1,469,414  1.05 (1.00, 1.11)   
ptrend 
   
0.13 
    
0.04 0.84 
Categories (g/day)                     
Non consumers   86   578,541 0.94 (0.71, 1.23) 
 
 51 176026.5 1.26 (0.89, 1.77) 
 0.1 - 4.9 182  1,261,449 1.00 (Ref) 
 
105 439200.4 1.00 (Ref) 
 5 - 14.9 126 879,891 0.99 (0.79, 1.25) 
 
 88 360975.2 0.91 (0.68, 1.22) 
 15 - 29.9  60 359,073 1.08 (0.82, 1.50) 
 
 73 227177.8 1.19 (0.87, 1.63) 
 30 - 59.9  28 176,457 0.93 (0.65, 1.48) 
 
 71 193786.8 1.25 (0.91, 1.73) 
 
≥ 60  12 30,799 2.17 (1.18, 3.99) 
 
 34 72247.58 1.50 (1.00, 2.28) 
 pWald5       0.14         0.10 0.41 
1 Models were stratified by centre, age at recruitment and sex. Systematic adjustment was undertaken for smoking status, physical activity level, educational attainment, 
diabetes status, BMI, height, and an indicator variable for drinkers; 
2 12g of alcohol correspond to about one standard glass of either wine, beer or spirits/liquors; 
3 Models included interaction terms between baseline alcohol use and a smoking indicator (0=never smokers; 1=current smokers), keeping as reference category the group of 
light alcohol users (0.1–4.9 g/day) among never smokers, whereas former smokers and participants without information on their smoking status were excluded; 
4 Differences in HRs were assessed comparing the log-likelihood of models with and without interaction terms between alcohol and smoking status to one degree of freedom 
χ
2
 distribution for analyses in continuous, and to five degrees of freedom χ2 distribution for analyses in categories; 
5 P-value was determined using a Wald test for contrasts according to a χ2 distribution with five degrees of freedom. 
 
 
 
 Figure 2. Hazard Ratio (HR) functions and corresponding 95% confidence intervals (95% CI) describing the linear (dark blue) and the 
curvilinear (light blue) dose–response relationship between baseline and lifetime alcohol intake (g/day) and PC risk, according to pancreatic 
cancer frequencies in men. 
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 Supplementary Figure 1. Lifetime intake of beer, wine and spirits/liquors (g/day) and Hazard Ratio (HR) of pancreatic cancer in men and 
women. 
 
1 Models for lifetime alcohol intake by subtypes were stratified by center and age at recruitment. Systematic adjustment was undertaken for smoking intensity, physical 
activity level, educational attainment, diabetes status, BMI, height, duration of subtype drinking, time since quitting subtype drinking, an indicator variable for drinkers of the 
subtype under analysis, and lifetime energy intake from other alcohol subtypes; 
2 Wald tests for overall significance across categories were performed according to the χ2 distribution with degrees of freedom equal to the number of categories minus one. 
Trend tests were performed for continuous variable;  
3 The category of light drinkers was used as the reference category (0.1-2.9 g/day for beer and wine, and 0.1-1.9 g/day for spirits/liquors;  
4 12g of alcohol correspond to about one standard glass of either wine, beer or spirits/liquors.  
 
Supplementary Figure 2: Associations between alcohol intake per 12g/day increase and PC risk (and associated 95% CI) by country of origin, for 
men and women combined. P-value for heterogeneity was equal to 0.33, and was obtained by comparing the log-likelihood difference of models 
with and without interaction terms to a chi-square statistics with 9 degrees of freedom.  
 
 
 
 
 
 Supplementary Table 1. Sensitivity analysis for adjustment by history of chronic pancreatitis (Z) via external information in the relationship 
between baseline alcohol intake (X) and risk of pancreatic cancer (D).  
 
Estimates of HRDX4 
pZ01 RRZX2 RRDZ3 = 1.5 2 2.5 5 10 15 
0.005 2.0   1.64 1.63 1.63 1.61 1.57 1.54 
0.01 2.0 1.63 1.62 1.62 1.58 1.52 1.46 
0.02 2.0 1.62 1.61 1.60 1.53 1.43 1.36 
0.005 4.0 1.63 1.62 1.60 1.55 1.46 1.38 
0.01 4.0 1.62 1.59 1.57 1.48 1.32 1.21 
0.02 4.0 1.60 1.56 1.52 1.36 1.15 1.02 
0.005 6.0 1.62 1.60 1.58 1.50 1.36 1.24 
0.01 6.0 1.60 1.57 1.53 1.39 1.18 1.04 
0.02 6.0   1.57 1.51 1.45 1.23 0.98 0.83 
1
 Prevalence of chronic pancreatitis among baseline moderate drinkers; 
2
 Chronic pancreatitis RR estimates associated with baseline alcohol intake;  
3
 Pancreatic cancer RR estimates associated with chronic pancreatitis; 
4
 Estimates of pancreatic cancer Hazard Ratios associated with baseline alcohol intake adjusted for chronic pancreatitis. The pancreatic cancer HR estimate for heavy drinkers 
(>60g/day) compared to the reference category of moderate drinkers (0.1-4.9g/day) not adjusted for chronic pancreatitis was 1.64. 
 
 
